Results 151 to 160 of about 4,998,947 (297)
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Causal effects and mediation pathways of circulating plasma proteins on osteoporosis: a two-sample and two-step Mendelian randomization study. [PDF]
Wang H, Zhou W, Huang Y, Li Y, Zhang K.
europepmc +1 more source
STUDIES ON THE PHYSIOLOGICAL ACTION OF SOME PROTEIN DERIVATIVES
Frank P. Underhill, Michael Ringer
openalex +1 more source
THE PLASMA PROTEINS IN RELATION TO BLOOD HYDRATION [PDF]
John P. Peters +2 more
openalex +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
Empathi: embedding-based phage protein annotation tool by hierarchical assignment. [PDF]
Boulay A +4 more
europepmc +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop +10 more
wiley +1 more source
Deciphering the dialogue between the bovine blastocyst and the uterus: embryo-induced alterations in extracellular vesicle protein content from an ex vivo model and the in vivo environment. [PDF]
Mazzarella R +12 more
europepmc +1 more source
THE ENZYMATIC SYNTHESIS OF PROTEIN. V
Hardolph Wasteneys, Henry Borsook
openalex +1 more source
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source

